The role of notch and gamma-secretase inhibition in an ovarian cancer model

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 801-808

  Shah, Monjri M ^a   Zerlin, Marielba ^b   Li, Blake Y ^b   Herzog, Thomas J ^b,c   Kitajewski, Jan K ^b,c   Wright, Jason D ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Gamma secretase inhibitor; Model; Notch; Ovarian cancer

Indexed keywords

2 CHLORO 3 (3,4 DICHLOROPHENYL) 1 ISOPROPYL 4 METHYLIMIDAZOLIUM CHLORIDE; CISPLATIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JAGGED1; METHYLTHIAZOLE TETRAZOLIUM; NOTCH RECEPTOR; NOTCH3 RECEPTOR; PLACEBO; PROTEIN DELTA LIKE4; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; RECEPTORS, NOTCH;

EID: 84875881167     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society 2010.
2. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
3. Choi JH, Park JT, Davidson B, Morin PJ, Shih Ie M and Wang TL: Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68: 5716-5723, 2008.
4. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster JC: Activating mutations of Notch1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271, 2004.
5. Sun Y, Gao X, Liu J, Kong Q-Y, Wang X-W, Chen X-Y, Wang Q, Cheng Y-F, Qu X-X and Li H: Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Archives of Pathologic Laboratory Medicine 135: 451-458, 2011.
6. Koch U and Radtke F: Notch and cancer: a double-edged sword. Cell Mol Life Sci 64: 2746-2762, 2007.
7. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
8. Hopfer O, Zwahlen D, Fey MF and Aebi S: The Notch pathway in ovarian carcinomas and adenomas. British Journal of Cancer 93: 709-718, 2005.
9. Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY and An HJ: Prognostic significance of Notch gene expression in ovarian serous carcinoma. Cancer Sci 101: 1977-1983, 2010.
10. Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM and Wang TL: Notch3 gene amplification in ovarian cancer. Cancer Res 66: 6312-6318, 2006.
11. Rose SL, Kunnimalaiyaan M, Drenzek J and Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol Oncol 117: 130-133, 2010.
12. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW and Span PN: Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85: 154-159, 2005.
13. Outtz HH, Wu JK, Wang X and Kitajewski J: Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol 185: 4363-4373, 2010.
14. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L and Foreman KE: Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 30: 3853-3867, 2010.
15. Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI and Nefedova Y: Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther 9: 3200-3209, 2010.
16. Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR and Winter CG: Inhibition of Notch signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 69: 3060-3068, 2009.
17. Park JT, Chen X, Trope CG, Davidson B, Shih Ie M and Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177: 1087-1094, 2010.
18. Rose SL: Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer 19: 564-566, 2009.
19. Wang M, Wu L, Wang L, Xin X. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun 393: 144-149, 2010.
20. Fernandez-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytes A, Real FX, Capella G, Mayo MW, Espinosa L and Bigas A: Nuclear IKK activity leads to dysregulated Notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA 104: 276-281, 2007.
21. Chen X, Stoeck A, Lee SJ, Shih Ie M, Wang MM and Wang TL: Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling pathways in ovarian cancer. Oncotarget 1: 210-218, 2010.
22. Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, Nannya Y, Suzuki R, Ota S, Ota Y, Izutsu K, Sakata-Yanagimoto M, Hangaishi A, Yagita H, Fukayama M, Seto M, Kurokawa M, Ogawa S and Chiba S: Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 100: 920-926, 2009.
23. Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M and Chen H: Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol 18: 1506-1511, 2011.
24. Spannuth WA, Sood AK and Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clinical Practice 5: 194-204, 2008.
25. Burger RA: Phase II trial of bevacizumab in persistent of recurrent epithelial ovarian cancer (EOC) or primary peritonieal cancer (PPC): a Gynecology Oncology Group (GOG) study. Journal of Clinical Oncology 25: 5165-5171, 2007.
26. Cannistra SA. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology 25: 5180-5186, 2007.
27. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X, Shawber CJ, Kandel JJ, Yamashiro DJ and Kitajewski J: A Notch1 ectodomain construct inhibits endothelial Notch signaling, tumor growth, and angiogenesis. Cancer Res 68: 4727-4735, 2008.
28. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
29. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL and Jain RK: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563, 2004.
30. Zaghloul N, Hernandez SL, Bae JO, Huang J, Fisher JC, Lee A, Kadenhe-Chiweshe A, Kandel JJ and Yamashiro DJ: Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol 34: 401-407, 2009.